Trials / Completed
CompletedNCT05776121
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
A Multiple Ascending Doses Study of ZB001 in Chinese Patients With Thyroid-Associated Ophthalmopathy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Zenas BioPharma (USA), LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics（PK）/pharmacodynamics (PD) profile of ZB001 in Chinese patients with Thyroid Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZB001 for injection | Dose Cohort1 (3 mg/kg) ZB001 four IV injections |
| DRUG | ZB001 for injection | Dose Cohort2 (10 mg/kg) ZB001 four IV injections |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2024-04-17
- Completion
- 2024-04-17
- First posted
- 2023-03-20
- Last updated
- 2025-04-11
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05776121. Inclusion in this directory is not an endorsement.